Laurent Pharmaceuticals
↗Montreal, Quebec, Canada
Laurent Pharmaceuticals is a clinical-stage biopharmaceutical company founded in 2012 as a spinoff from McGill University, focusing on the discovery and development of novel therapeutics targeting inflammatory and fibrotic diseases. The company specializes in the modulation of cell membrane lipids as a novel approach to address life-threatening conditions caused by unbalanced immune-inflammatory responses. Their proprietary lead drug candidate, LAU-7b, is a unique oral formulation of fenretinide, an atypical retinoid with a well-documented safety profile in over 3,000 patients. The company is leveraging 10+ years of clinical development experience to advance LAU-7b through multiple Phase 2/3 clinical trials for serious indications including COVID-19, Long COVID, Cystic Fibrosis, and Idiopathic Pulmonary Fibrosis, representing a host-directed approach to treating viral and inflammatory diseases.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:-
Industry:Biotechnology
Sub-Industry:Inflammatory & Fibrotic Disease Therapeutics
SIZE & FINANCIALS
Employees:1-50
Founded:2012
Ownership:private
Status:operating
FUNDING
Stage:Series A
Total Raised:$14.46M
Investors:National Research Council Canada (NRC), Government of Quebec, Cystic Fibrosis Foundation, Anges Quebec, AQC Capital, Keiretsu Forum, Cherrystone Angel Group, Denniston Family Office, Groupe Roski, Keiretsu Capital, Aligo Innovation, BioMed Propulsion Fund
PIPELINE
Stage:Phase 2/3
Lead Drug Stage:Phase 2/3 (COVID-19, Long COVID); Phase 2 (CF, IPF)
Modalities:Small molecule, Atypical retinoid, Host-directed therapy
Active Trials:4
Trial Phases:Phase 2: 2 | Phase 3: 2
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:McGill University (McGill spinoff, continued research collaboration), Cystic Fibrosis Foundation (investor and patient advocacy partner), Government of Canada - National Research Council Industrial Research Assistance Program (IRAP) - financial support for ESSOR Long COVID trial, Government of Quebec - BioMed Propulsion Fund (CAD 2.7M loan facility)
COMPETITION
Position:Emerging
Competitors:Alladapt Immunotherapeutics, NovaBay Pharmaceuticals, Secura Bio, Alnylam, Ultragenyx, BioMarin Pharmaceutical, Verona Pharmaceuticals (Ensifentrine for CF), Vertex Pharmaceuticals (VX-121/TEZ/VX-561 for CF)
LEADERSHIP
Key Executives:
Radu Pislariu - President and Chief Executive Officer, Co-founder
Patrick Colin - Acting Chief Development Officer, Co-founder
Jean-Marie Houle - Vice-President, Clinical Development
Scientific Founders:Radu Pislariu, MD (Co-founder, McGill-affiliated researcher), Patrick Colin, BPharm, PhD (Co-founder, McGill-affiliated researcher)
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Laurent Pharmaceuticals. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.